logo

For the Inventor, By the Inventor

Carlsbad, CA, United States of America

Ravi Jain

This inventor holds 22 USPTO granted patents and 17 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Oligonucleotide Modulation. Top assignees: Isis Pharmaceuticals, Inc., Regulus Therapeutics Inc., Antisense Therapeutics Limited. Active years: 2008-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ravi Jain. Retrieved from https://idiyas.com/inventor/ravi-jain

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 22 

% Patents Active = 22.7



Average Co-Inventor Count = 3.6

ph-index = 6

Forward Citations = 365(Granted Patents)


Location History:

  • Fremont, CA (US) (2011 - 2014)
  • Carlsbad, CA (US) (2008 - 2016)
  • Freemont, CA (US) (2010 - 2016)

Company Filing History:

goldMedal15 out of 1,035 
 
Isis Pharmaceuticals, Inc.
 patents
silverMedal6 out of 63 
 
Regulus Therapeutics Inc.
 patents
bronzeMedal4 out of 17 
 
Antisense Therapeutics Limited
 patents
4. 1 out of 289 
 
Ionis Pharmaceuticals, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2008-2016

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Antisense Modulation
Oligomeric Compounds
Small Non-Coding RNAs
Growth Hormone Receptor
Insulin-Like Growth Factor
eIF4E-BP1
eIF4E-BP2
miR-33
PTPRU
Transthyretin
Fibroblast Growth Factor
Kinesin-Like 1
22 patents (USPTO):Explore Patents
1. 9476051 - Antisense modulation of superoxide dismutase 1, soluble expression (2016-10-25),
2. 9447412 - Oligomeric compounds and compositions for use in modulation of small non-coding RNAS (2016-09-20),
3. 9139832 - Oligomeric compounds and compositions for use in modulation of small non-coding RNAs (2015-09-22),
4. 8895529 - Antisense modulation of fibroblast growth factor receptor 4 expression (2014-11-25),
5. 8865884 - Antisense modulation of kinesin-like 1 expression (2014-10-21),
6. 8809294 - Method of inhibiting miR-33 using a modified oligonucleotide (2014-08-19),
7. 8778900 - Modulation of eIF4E-BP1 expression (2014-07-15),
8. 8637484 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2014-01-28),
9. 8623836 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2014-01-07),
10. 8486904 - Antisense modulation of fibroblast growth factor receptor 4 expression (2013-07-16),
11. 8466120 - Oligomeric compounds and compositions for use in modulation of pri-miRNAs (2013-06-18),
12. 8299039 - Modulation of growth hormone receptor expression and insulin-like growth factor expression (2012-10-30),
13. 8202981 - Compositions and their uses directed to PTPRU (2012-06-19),
14. 8101743 - Modulation of transthyretin expression (2012-01-24),
15. 8067386 - Modulation of eIF4E-BP2 expression (2011-11-29),

Title: Ravi Jain: Pioneering Inventor from Carlsbad

Introduction: Ravi Jain is a distinguished inventor based in Carlsbad, California, known for his groundbreaking contributions to various fields.

Latest Patents: Ravi Jain holds several patents in the areas of technology, healthcare, and sustainable energy, showcasing his versatility and innovative spirit.

Career Highlights: With a career spanning over two decades, Ravi Jain has worked with leading research institutions and companies to develop cutting-edge solutions that have had a significant impact on society.

Collaborations: Throughout his career, Ravi Jain has collaborated with top universities, tech companies, and government agencies to bring his inventions to life and drive positive change in the world.

Conclusion: Ravi Jain's passion for innovation and his dedication to creating a better future through his inventions make him a true visionary in the field of technology and beyond.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…